Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811298 | 0.87 | CA14 (0.38) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL752842 | 0.85 | HDAC6 (0.36) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL2486588 | 0.84 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL18285886 | 0.81 | CA14 (0.43) | CA14HDAC6HDAC1HDAC2POLB | |
| SCHEMBL24137970 | 0.81 | CA14 (0.40) | CA14HDAC6HDAC1HDAC2POLB | |
| SCHEMBL8522505 | 0.80 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL499576 | 0.80 | HDAC6 (0.38) | CA14HDAC6HDAC1HDAC2 | |
| SCHEMBL18759031 | 0.78 | CA14 (0.42) | CA14HDAC6HDAC1HDAC2MLYCD | |
| SCHEMBL23857521 | 0.78 | CA14 (0.45) | CA14HDAC6HDAC1HDAC2POLB | |
| SCHEMBL20783203 | 0.76 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2266958-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | CA14 4756/4885HDAC6 2258/4885HDAC1 307/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CA14 4336/4885HDAC6 1915/4885HDAC1 367/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | CA14 4336/4885HDAC6 1915/4885HDAC1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.